## INTERNATIONAL SEARCH REPORT

International application No.

Int.C	IFICATION OF SUBJECT MATTER  16 C07D207/04, 213/56, 295/22, 209/ 239/48,277/28, 07/85, 495/04, 491 217/26, 217/26,215/48, 235/08, 47: 31/445, 31/53, 31/54, 31/435, 3; In ternational Patent Classification (IPC) or to both national	1/048, 513/04, 498/04, 233/04 1/04. A61K31/44, 31/495, 31/5	, 211/34, 233/20, ]			
B FIELDS	SEARCHED	(4)				
Minimum do Int.C	Minimum documentation searched (classification system followed by classification symbols)  Int.Cl <sup>6</sup> C07D207/04, 213/56, 295/22, 209/44, 417/12, 409/04, 333/68, 401/04, 405/04, 239/48, 277/28, 307/85, 495/04, 491/048, 513/04, 498/04, 233/64, 211/34, 233/26, 217/26, 217/26, 215/48,235/08, 471/04,A61K31/44, 31/495, 31/55, 31/505, 31/535, 31/445, 31/53, 31/54, 31/435, 31/415, 31/47					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) REGISTRY (STN), CA (STN), CAOLD (STN), CAPLUS (STN)						
C. DOCU	MENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where app	ropriate, of the relevant passages	Relevant to claim No.			
X	WO, 96/40679, A1 (RHONE-POULENC INC.), 19 December, 1996 (19.12.96) & EP, 853618, A1 & US, 56123 & JP, 11507368, A & CN, 11903	RORER PHARMACEUTICALS	1-22			
<b>X</b>	WO, 96/10022, A1 (ZENECA LIMITE 04 April, 1996 (04.04.96) & EP, 783500, A1 & US, 59655 & JP, 10506122, A		1-22			
х	WO, 98/21188, A1 (ZENECA LIMITE 22 May, 1998 (22.05.98) & EP, 937048, A1 & AU, 97487	·	1-22			
x	WO, 97/29104, A1 (ZENECA LIMITE 14 August, 1997 (14.08.97) & EP, 880516, A1 & AU, 97155	:	1-22			
		·				
Furth	er documents are listed in the continuation of Box C.	See patent family annex.				
Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier document but published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "P" document published after the international filing date but later than the priority date claimed document priority date and not in conflict with the application but cite understand the principle or theory underlying the invention document of particular relevance; the claimed invention can document of particular relevance; the claimed invention can considered to involve an inventive step when the document combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family			he application but cited to lerlying the invention claimed invention cannot be cred to involve an inventive e claimed invention cannot be chained invention cannot be the document is a documents, such n skilled in the art			
Date of the	e actual completion of the international search November, 1999 (09.11.99)	Date of mailing of the international sea 30 November, 1999 (	rch report 30.11.99)			
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer				
Facsimile No.		Telephone No.				

International application No.

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	WO, 98/25611, Al (RHONE-POULENC RORER PHARMACEUTICALS INC.), 18 June, 1998 (18.06.98) & EP, 944386, Al & AU, 9855182, Al	1-8,10-22 9		
X A	WO, 98/24784, Al (RHONE-POULENC RORER PHARMACEUTICALS INC.), ll June, 1998 (11.06.98) & EP, 894088, Al & AU, 9860121, Al	1-8,10-22		
X A	JP, 04-342579, A (Akurasu K.K.), 30 November, 1992 (30.11.92) (Family: none)	1,9-22 2-8		
X A	JP, 57-040474, A (Hiroyoshi Hidaka), 06 March, 1982 (06.03.82) & EP, 46572, A2 & US, 4510307, A	1-3,9-22 4-8		
X A	WO, 96/33196, A1 (ABBOTT LABORATORIES), 24 October, 1996 (24.10.96) & EP, 821685, Q1 & JP, 11-503758, A & US, 5643922, A	1,9-22 2-8		
X A	US, 5654305, A (ABBOTT LABORATORIES), 05 August, 1997 (05.08.97) (Family: none)	1,9-22 2-8		
X A	WO, 97/28141, A1 (PIERRE FABRE MEDICAMENT), 07 August, 1997 (07.08.97) & EP, 880512, A1	1,9-22		
X A	WO, 97/28139, A1 (PIERRE FABRE MEDICAMENT), 07 August, 1997 (07.08.97) & FR, 2744450, A1	1,9-22 2-8		
X A	WO, 97/03963, A1 (Kyowa Hakko Kogyo Co., Ltd.), 06 February, 1997 (06.02.97) & EP, 782987, A1 & US, 58910902, A	1,2,5,9-12 3,4,6-8,13-22		
X A	WO, 98/06705, A1 (ZENECA LIMITED), 19 February, 1998 (19.02.98) & EP, 925286, A1 & AU, 9737017, A1	1-4,9-12 5-8,13-22		
X	<pre>JP, 03-258763, A (Asahi Chemical Industry Co., Ltd.), 19 November, 1991 (19.11.91) (Family: none)</pre>	1,9-12 2-8,13-22		
X A	JP, 02-184673, A (Yoshitomi Pharmaceutical Industries, Ltd.), 19 July, 1990 (19.07.90) (Family: none)	1,9-12 2-8,13-22		
X A	<pre>JP, 01-316383, A (Yoshitomi Pharmaceutical Industries, Ltd.), 21 December, 1989 (21.12.89) &amp; EP, 364598, Al</pre>	1,9-12 2-8,13-22		
X A	JP, 58-49366, A (Otsuka Pharmaceutical Co., Ltd.), 23 March, 1983 (23.03.83) (Family: none)	1,9-12 2-8,13-22		
X A	WO, 96/41173, A1 (RESEARCH CORPORATION TECHNOLOGIES INC.), 19 December, 1996 (19.12.96) (Family: none)	1,9-11 2-8,12-22		

## INTERNATIONAL SEARCH REPORT

International application No.

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	WO, 99/16747, Al (Daiichi Pharmaceutical Co., Ltd.), 08 April, 1999 (08.04.99) & AU, 9892806, Al	1-22
РХ	WO, 99/40075, A1 (Takeda Chemical Industries, Ltd.), 12 August, 1999 (12.08.99) (Family: none)	1-22
PX	WO, 99/37304, A1 (RHONE-POULENC RORER PHARMACEUTICALS INC.), 29 July, 1999 (29.07.99) (Family: none)	1-22
PX	WO, 99/33805, A1 (Mochida Pharmaceutical Co., Ltd.), 8 July, 1999 (08.07.99) & AU, 9916923, A1	1-22
PX	WO, 99/31092, A1 (MERCK PATENT GMBH), 24 June, 1999 (24.06.99) & DE, 19755268, A1	1-22
PX	WO, 99/16751, A1 (MERCK PATENT GMBH), 8 April, 1999 (08.04.99) & DE, 19743435, A1	1-22
PX	WO, 98/54164, A1 (TAKEDA CHEMICAL INDUSTRIES, LTD.), 3 December, 1998 (03.12.98) & JP, 11-236372, A & AU, 9874534, A1	1-22
PX	WO, 99/26932, A1 (AXYS PHARMACEUTICALS, INC.), 3 June, 1999 (03.06.99) & AU, 9916071, A1	1-22
<b>PX</b>	WO, 98/47876, A1 (AKZO NOBEL N.V.), 29 October, 1998 (29.10.98) & AU, 9876486, A1	1-22
PΧ	WO, 99/06367, A1 (SMITHKLINE BEECHAM CORPORATION), 11 February, 1999 (11.02.99) & AU, 9887632, A1	1-22
PX PA	WO, 99/01434, A1 (BRISTOL-MYERS SQUIBB COMPANY), 14 January, 1999 (14.01.99) (Family: none)	1,10-22 2-9,13-22
		1

## INTERNATIONAL SEARCH REPORT

International application No.

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)  This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following the sheet of the state of the sheet of the sh	wing reasons:
1. Claims Nos.: 23-26 because they relate to subject matter not required to be searched by this Authority, namely:	
because they relate to subject matter not required to be determined by	rany which
The subject matter of claims 23 to 26 relates to a method for treatment of the human body by the	apy, which
does not require an international search report by this International Search Authority.	
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirement	nts to such an
extent that no meaningful international search can be carried out, specifically:	
3. Claims Nos.:	0.1.6463
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of F	Kule 6.4(a).
Box II -Observations where unity of invention is lacking (Continuation of item 2 of first sheet)	
This International Searching Authority found multiple inventions in this international application, as follows:	
This income out of the second	
1. As all required additional search fees were timely paid by the applicant, this international search report covers	ers all searchable
claims.	
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not	invite payment
As all searchable claims could be searched without effort justifying an additional fee, and of any additional fee.	• •
3. As only some of the required additional search fees were timely paid by the applicant, this international sear	rch report covers
only those claims for which fees were paid, specifically claims Nos.:	
·	
4. No required additional search fees were timely paid by the applicant. Consequently, this international	
search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	
Remark on Protest	
No protest accompanied the payment of additional search fees.	